What Factors Increase the Chances of Success?
RS spent years quantitatively analyzing all of global biopharma's historical successes and failures in order to elucidate the specific factors that most impact a drug's odds of clinical success, and a company's chances of economic success. What if a new systematic set of principles and strategies based on these critical factors could significantly improve success rates? 1, 2, 5
What Innovations Enhance Risk-Reward?
Today ~99.7% of the world’s institutional investors have zero exposure to biotech, with only ~250 firms making 2+ therapeutics investments per year 3. What if new tech-enabled operating models and more efficient R&D strategies could improve the sector's accessibility and economic appeal, expanding capital availability for the drugs and companies that truly "deserve to be made"?
Are the Best Discoveries Made into Medicines?
Analysis of all current biomedical knowledge on the RS data platform reveals the surprising finding that ~75% of all target-disease opportunities with strong cumulative evidence of links have never been tried: 23,000+ opportunities spanning 3,800+ individual targets for 4,200+ diseases are just waiting to be made into promising new medicines. 4